BioSpace News Archive

CANTEL MEDICAL CORP. announced several business and financial updates in light of the ongoing COVID pandemic.

- Dry Eye Disease Phase 2 Study Remains on Track - Data Anticipated in 4Q20 - $89 Million in Cash at March 31, 2020 - Teleconference and Webcast to be held on May 12, 2020

In terms of revenue, the global ileostomy market is projected to expand at a CAGR of ~7% during the forecast period, due to numerous factors, about which, TMR offers comprehensive insights and forecasts in the global Ileostomy market report.

Industrial microbiology encompasses the use of microorganisms and their metabolites for a wide variety of industrial products.

According to the report, the medical device cleaning market was valued at ~US$ 2.8 Bn in 2018 and is expected to expand at a CAGR of ~5% during the forecast period.

Blood plasma and its derivatives form a significant source of medicines.

International medical imaging IT and cybersecurity company Sectra will install the radiology and breast imaging modules of its enterprise imaging solution at Mayfair Diagnostics’ facilities in Canada.

Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today presented preclinical data supporting its lead artificial antigen-presenting cell (aAPC) program, RTX-321, for the potential treatment of HPV 16-positive tumors at the American Society of Gene and Cell Therapy 23rd Annual Meeting. The meeting is being he

IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics, provided a business update and announced financial results for the first quarter ended March 31, 2020 .

Invivoscribe is pleased to announce that their LeukoStrat® CDx FLT3 Mutation Assay was submitted to regulatory authorities in China in April in support of the Astellas New Drug Application submission of XOSPATA® for treatment of adult patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation.